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Polygenic risk score: use in migraine
research
Mona Ameri Chalmer*, Ann-Louise Esserlind, Jes Olesen and Thomas Folkmann Hansen
Abstract
Background: The latest Genome-Wide Association Study identified 38 genetic variants associated with migraine.
In this type of studies the significance level is very difficult to achieve (5 × 10− 8) due to multiple testing. Thus, the
identified variants only explain a small fraction of the genetic risk. It is expected that hundreds of thousands of
variants also confer an increased risk but do not reach significance levels. One way to capture this information is by
constructing a Polygenic Risk Score. Polygenic Risk Score has been widely used with success in genetics studies
within neuropsychiatric disorders. The use of polygenic scores is highly relevant as data from a large migraine Genome-
Wide Association Study are now available, which will form an excellent basis for Polygenic Risk Score in migraine studies.
Results: Polygenic Risk Score has been used in studies of neuropsychiatric disorders to assess prediction of disease status
in case-control studies, shared genetic correlation between co-morbid diseases, and shared genetic correlation between a
disease and specific endophenotypes.
Conclusion: Polygenic Risk Score provides an opportunity to investigate the shared genetic risk between known
and previously unestablished co-morbidities in migraine research, and may lead to better and personalized
treatment of migraine if used as a clinical assistant when identifying responders to specific drugs. Polygenic Risk
Score can be used to analyze the genetic relationship between different headache types and migraine endophenotypes.
Finally, Polygenic Risk Score can be used to assess pharmacogenetic effects, and perhaps help to predict efficacy of the
Calcitonin Gene-Related Peptide monoclonal antibodies that soon become available as migraine treatment.
Keywords: Migraine genetics; Genome-Wide Association Studies; Polygenic Risk Score; pleiotropy; endophenotype.
Review
Introduction
Migraine is a prevalent and disabling disease [1] with an
incompletely understood etiopathology. The hereditary
component of migraine, i.e. the proportion of individual
differences explained by genetic variation in migraine, is
estimated to be between 38 and 53% and is likely to arise
from the combined effect of many common risk variants
each with small effect sizes, thus characterizing migraine
as a common complex, polygenic disease [2–4]. There is
a wide range of allelic variation in human disease genes,
and one common form of variation is the Single Nucleo-
tide Polymorphism (SNP). SNPs have been valuable as
genomic “markers” in the search for causal variants that
influence susceptibility to common diseases, or as causal
variants with marginal effect. The most common way to
discover common variants is through Genome-Wide As-
sociation Studies (GWAS). A GWAS is based on the
common-disease common-variant (CDCV) hypothesis
and seeks to explore many SNPs randomly distributed
across the human genome. A GWAS is a relatively sim-
ple way to test multiple SNPs and their contribution to
disease susceptibility by comparing risk allele frequen-
cies in cases against healthy controls [5]. To date, 38
genetic loci with common SNPs associated with mi-
graine have been discovered [6], where the individual
SNP only explains a marginal proportion of the genetic
variance. Calculating the Polygenic Risk Score (PRS) is
one way to assess the additive effect of several (associ-
ated) SNPs. Using a PRS calculated from sufficiently
powered studies is a better way to estimate the genetic
variance of the disease assessed than the individual
genome-wide significant SNPs [7]. Further, some PRS
methods allow researchers to assess genetic overlaps be-
tween comorbid diseases, i.e. genetic correlations, which
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have previously only been identified by epidemiological
or clinical studies.
Our aim is here to describe the concept of the PRS ap-
proach to facilitate understanding of PRS analysis among
migraine researchers with a limited expertise in molecu-
lar genetics. PRS has been studied sparsely in migraine.
Thus, we use examples from neuropsychiatric disorders
as they are also common brain disorders, and PRS has
been widely used with great success within this field.
Finally, we discuss the opportunities offered by key PRS
approaches in future migraine research.
Methods
We identified peer-reviewed studies applying polygenic
methods in schizophrenia, bipolar disorder, major de-
pressive disorder, and attention-deficit/hyperactivity dis-
order (ADHD) as classified by the DSM-IV using the
following search terms for each of the three conditions:
“Polygenic” and “risk”; “polygenic” and “analysis”; “poly-
genic” and “variation”; “polygenic” and “methods” in ab-
stracts, or MESH, or text terms in Medline. We then
scanned the reference lists from the selected articles for
key references to find additional studies. The search was
limited to English language publications no older than
nine years (published from January 2009 to January
2018). Exclusion criteria were animal studies and re-
views. Abstracts and titles were rated independently
(two researchers: MAC and ALE). The articles were cat-
egorized into two groups: Group one included articles
where the main focus in the papers was PRS, and/or pa-
pers where the PRS methods were used, and thus rele-
vant for the review; group two included articles that did
not describe or use a polygenic risk scoring method, and
thus not relevant for the review. Abstracts that were
relevant to migraine research included genetic risk scor-
ing of complexly inherited neuropsychiatric traits.
Abstracts on genetic scoring in all types of cancers were
not included, because cancer differs markedly from that
of brain disorders, such as migraine. The search yielded
146 articles; out of which 38 fulfilled the inclusion cri-
teria and were included in the review.
Understanding the polygenic risk score
A detailed review of the methodology of polygenic score
methods is beyond the scope of this article and has been
described elsewhere [7, 8]. PRS analysis allows for more
genetic information to be assessed from genomic data
than a simple threshold approach, such as the GWAS
threshold, which conventionally uses a p-value threshold
of 5 × 10− 8 to avoid issues of false positive findings due
to multiple testing. The PRS approach relies on the
theory that heritability, i.e. the amount of phenotypic
variation explained by genetic components, of complex
traits, is caused by an additive effect of multiple
common gene variants with small effect sizes, a so-
called polygenetic effect that is traditionally identified by
GWAS. It was initially introduced as a summary score
of the gene variants that are below the GWAS-
significant threshold value, but the score has also been
shown to be valuable when including variants that are
above the GWAS threshold.
To construct a PRS, an initial GWAS is done which is
considered the discovery sample. In an independent
sample with GWAS data, denoted the target sample, the
PRS is calculated for each individual by adding up the
risk alleles weighted by their odds ratios from the dis-
covery sample. It is then possible to evaluate the predic-
tion value of PRS using e.g. the coefficient of
determination from the regression analysis, also
expressed as R2 [9]. This can be done using different
significance thresholds (PT) of the data from the
discovery sample, thereby testing whether including
more information, i.e. SNPs, increases the power of
prediction. For successful construction of the PRS four
prerequisites has been suggested: The target and
discovery samples must be large (n > 2000 [7]); the
discovery sample must be at least as large as the target
sample; the phenotype investigated must be relatively
homogeneous; and the level of genetic variation
explained by common variants must be high [7]. We
used data from the latest migraine meta-analysis as dis-
covery sample [6] to conduct power calculations to esti-
mate the number of samples required to derive a
clinically useful predictor for migraine risk. We used the
statistical R package AVENGEME [7, 10, 11] and pro-
vided a power calculation based on two different mi-
graine prevalences in the target sample and for three
different PT, see fig. 1. A sample size of 300, given PT of
1 × 10− 4 and 0.05, provides a study power of 80%,
however, by using the genome-wide PT (5 × 10
− 8) a
sample size of more than 800 samples is needed,
assuming a migraine prevalence of 0.2. Large discovery
cohorts are needed to obtain decent power in smaller
target samples. This calls for large collaborations, e.g.
UK Biobank and International Headache Genetics
Consortium.
Lessons from genetic studies of neuropsychiatric
disorders
Since most neuropsychiatric disorders are common brain
disorders, we sought it relevant to retrieve inspiration to
migraine PRS studies from here. There have been several
studies on neuropsychiatric disorders using the PRS to as-
sess: Prediction of disease status in case-control studies,
shared genetic correlation between co-morbid diseases,
and shared genetic correlation between a disease and spe-
cific endophenotypes. We shall highlight key concepts of
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PRS analysis from neuropsychiatric genetics, focusing on
these polygenic approaches.
Prediction of case-control status
Purcell et al. prompted the use of nominal associated
SNPs in neuropsychiatric research in 2009 [9]. By creat-
ing a genetic risk score, the authors showed that the
power of a large GWAS could be applied to smaller
sample sizes and could predict case-control status.
Primarily, this was an investigation of a single disease
(schizophrenia) where the SNPs derived from the discov-
ery sample were tested in an independent schizophrenia
replication sample. The authors found that SNPs with
significance level PT < 0.05 were correlated with
schizophrenia in the target sample (P = 9 × 10− 19) and
explained approximately 3% of the genetic variance.
Table 1 gives an overview of the studies that have since
investigated the prediction of case-control status (risk
prediction) using PRS analysis. The studies show consist-
ent patterns across different phenotypes with significant
disease prediction capacity but low ability to explain
variance in genetic liability (between 0.2 and 5%).
Investigation of pleiotropy: The shared genetic risk
between distinct phenotypes
The ability of a genetic variant to associate with more
than one phenotype is referred to as pleiotropy. The
pleiotropic effect of the SNPs may indicate that different
diseases are genetically correlated [12, 13]. Polygenic
Fig. 1 AVENGEME [7] was used to calculate the study power (y-axis) given different target sample sizes (x-axis) for migraine. For the calculation
we used assumptions derived from Gormley et al.: Discovery cohort = 375.000; variance explained in the discovery sample = 0.1463; and a
prevalence of 0.158. Further, we assumed that the fraction of NULL SNPs is 0.95 and that the outcome is binary. The effects from Gormley et al.
are used to weigh the SNPs for calculating the PRS. We present six curves representing two different prevalences of migraine in the target
sample (circle = 0.2 and triangle = 0.5) given three different PT in the discovery sample (black = 5 × 10
− 8, red = 1 × 10− 4, and blue = 0.05
Table 1 Prediction of case control status using Polygenic Risk Score
Reference Discovery sample Target sample Outcome
Ruderfer et al. [51] 2794 cases (SCZ)
and 2976 controls
334 cases (SCZ) and 360 controls Variance explained by SCZ PRS was 5%. The PRS was higher in cases
than controls. Population stratification did not influence the outcome.
Chang et al. [52] 6989 cases (NHS) 3 of the 4 NHS-GWAS [53] sub-
studies were used as training sets
PRS was estimated by 3 different approaches: internal whole-genome
scoring and two external PRS weighting algorithms from independent
samples. The 3 PRS approaches explained 0.2% of the variance in
depressive symptoms.
Kauppi et al. [20] 9146 cases (SCZ)
and 12,111 controls
63 cases (SCZ) and 118 controls PRS was significantly higher in patients than controls, and a higher PRS
was associated with dysfunction of frontal lobe activation during work-
memory related tasks.
SCZ Schizophrenia, NHS Nurses’ Health Study, GWAS Genome Wide Association Study
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methods can be used to test the genetic correlation be-
tween two distinct diseases. As an example, a polygenic
score derived from a discovery sample from consortium
data in schizophrenia was applied to seven different tar-
get samples: One bipolar cohort and six other non-
neuropsychiatric cohorts [9]. The schizophrenia PRS
predicted bipolar disorder status but had no correlation
with non-neuropsychiatric traits. Thus, the study sup-
ported epidemiological results correlating the two dis-
eases [14]. The variance of genetic liability to bipolar
disorder explained by the polygenic score was small
(R2 = 0.019), but still a significant portion of the total
SNP heritability could be explained by the schizophrenia
PRS [9]. This approach gained further support from
studies conducted by the cross disorder group of the
Neuropsychiatric Genomics Consortium and it found
overlapping genetic loci, i.e. pleiotropy, for childhood-
onset diseases (ADHD and autism) and adolescent/adult
on-set diseases (bipolar disorder, major depressive dis-
order, and schizophrenia) [15]. Again, bipolar disorder
and schizophrenia were found to correlate, but also the
status of autism spectrum disorder could be predicted
by polygenic scores from both schizophrenia and bipolar
disorder. These studies have successfully shown that
PRS may identify pleiotropy.
PRS may also be used to identify a shared genetic
background of unknown co-morbid traits. Powell et al.
recently showed that an aggregate of common variants
conferring risk of schizophrenia and bipolar disorder
may underlie creativity in artists [16].
Studies investigating pleiotropy, using PRS are indexed
in Table 2. PRS is a significant predictor of pleiotropy,
but the variance of genetic liability is still low, ranging
from 0.1% to 2.1%.
Investigation of polygenic risk score and endophenotypes
Many complex genetic diseases are heterogeneous with
regards to e.g. symptomatology and age of onset. The
heterogeneity of these diseases may reflect the multifac-
torial and polygenic origin of the disease. Neuropsychi-
atric disorders and other neurological diseases like
migraine and other headache diseases are clinically
defined phenotypes that are not supported by measur-
able biomarkers. An endophenotype is a genetic-
epidemiological concept which aims to group behavioral
symptoms into more clear-cut phenotypes of a heritable
disease. Endophenotypes are assumed to detect the gen-
etic risk of disease regardless of the manifestation of the
disease phenotype, and may, therefore, define the bio-
logical etiology better than the clinical diagnosis [17].
Endophenotypes have been widely studied in neuro-
psychiatric research [17], in other brain diseases, e.g.
Alzheimer’s disease [18] as well as in other hereditary
diseases e.g. cystic fibrosis [19]. The definition and
criteria for endophenotypes used in neuropsychiatric re-
search are listed in Table 3.
An endophenotype of schizophrenia, dysfunction of
frontal lobe activation during work-memory related
tasks, has been associated with higher PRS for schizo-
phrenia [20]. These findings are further supported by
studies on healthy patients using both structural and
functional brain imaging in which the schizophrenia-
derived PRS showed to associate with the differences in
activity during verbal testing [21, 22]. Likewise, another
study found a non-significant trend in the differentiation
of bipolar disorder with and without psychosis using the
schizophrenia-derived PRS [23]. Further examples of
studies using PRS to dissect endophenotypes are listed
in Table 4.
Furthermore, PRS analysis has been used to probe dif-
ferent responses to pharmacological treatment as aber-
rant drug responses may be proxies or even regarded as
endophenotypes. A recent study found that PRS derived
from a meta-analysis of three genome-wide pharmacoge-
netic studies explained 0.5%–1% of the variance in
antidepressants-response in patients with major depres-
sive disorder [24]. Another study used PRS derived from
bipolar disorder to investigate whether a lack of re-
sponse to antidepressants could be explained by a high
PRS for bipolar disorder. The study did not show an as-
sociation between increasing PRS and lack of response
to antidepressants [25]. This shows that by investigating
treatment response using PRS, important and interesting
research questions may be answered.
Factors influencing polygenic risk score performance
It should be noted that the performance of the PRS is
influenced by several parameters such as the underlying
genetic architecture of the disease in terms of the num-
ber of causal variants and whether these have an additive
effect, the effect sizes of individual causal variants, and
allele frequency at the causal variants. As an example, a
larger discovery sample is necessary if the genetic archi-
tecture consists of many low frequent variants with
small effect sizes, as opposed to a genetic architecture
that has fewer frequent variants with relatively high ef-
fect sizes. Thus, the PRS performance relies on the sam-
ple size; by increasing the discovery sample, the variance
explained increases, which further increases the accuracy
of the PRS for each individual. Furthermore, it has been
estimated that when a target sample reaches ~ 2000
cases there should be sufficient power to detect a vari-
ance that is different from zero [7, 8]. Other factors that
may influence PRS performance may be the heterogen-
eity of the phenotype, which paradoxically is often com-
promised in GWAS studies in the need for large sample
sizes and better prediction power.
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It is important that the discovery and target sample are
independent. Thus, patients of the same ethnicity as the
target sample are often excluded from the discovery sam-
ple to avoid an overestimation of the effects of the PRS.
Suggested application of polygenic risk score
analysis to migraine research
In this review we have described a method to explore
the genetic architecture of common complex brain dis-
orders. As migraine and other headache disorders re-
semble neuropsychiatric disorders on the complexity,
the polygenetic nature, and both being common brain
disorders, we have introduced PRS analysis by summar-
izing experiences from studies of neuropsychiatric disor-
ders. As large migraine GWAS datasets are now
available [6] it is now possible to apply polygenic
methods in migraine research.
Investigation of pleiotropy in migraine
Most studies of shared genetics have been investigated
in bi- and multivariate twin model studies. These studies
were hampered by the need for large twin cohorts with
two or more traits of interest. A great opportunity is
therefore offered by PRS analysis which may confirm
these findings, and enable further investigation at a
genotype level. Two migraine studies using a PRS based
on small migraine GWAS datasets have already been
performed. These studies compared the PRS in migraine
and two important migraine co-morbidities; depression
and stroke. Ligthart et al. [26] found genetic components
shared between migraine and major depressive disorder
(MDD). The PRS derived from GWAS on MDD could
significantly predict the comorbid MDD and migraine
phenotype (P = 0.0015), but the MDD PRS could not
predict migraine without comorbid MDD (P = 0.058).
The correlation between migraine and ischemic stroke
has been investigated using data from the International
Headache Genetics Consortium’s migraine meta-analysis
from 2013 (discovery sample), which was applied to a
sample consisting of patients with stroke (target sample)
[27]. The study found genetic risk factors shared be-
tween migraine without aura (MO) and large arterial
stroke (p = 6.4 × 10− 28) as well as between MO and
cardio-embolic stroke (p = 2.7 × 10− 20). Recently, a study
in BioRxiv by Antilla et al. [28] suggested a limited
sharing of genetic risk between neurological and
psychiatric disorders in general. Although, migraine was
significantly correlated with ADHD (rg = 0.26, p = 8.81 ×
10− 8), Tourette Syndrome (rg = 0.19, p = 1.80 × 10
− 5),
and MDD (rg = 0.32, p = 1.42 × 10
− 22), suggesting that
migraine may share genetic risk with these disorders.
These are indeed interesting findings, and the latest and
largest migraine GWAS presents an opportunity to con-
firm these findings as well as to test pleiotropy for other
known migraine co-morbidities, e.g. autoimmune diseases
[29], thyroid diseases [30], pain disorders [31], fibromyal-
gia [32], and sleep [33]. Another known migraine co-
morbidity is endometriosis [34–36] and, very interestingly,
a study suggested that migraine and endometriosis are
genetically correlated (rg = 0.27, 95% CI: 0.06–0.47). Fur-
thermore, the relation between migraine and personality
traits may also be tested [37, 38]. PRS may lead to better
understanding of the disease and thus enable better choice
of treatment for migraine patients. One can even imagine
using PRS as a clinical assistant when choosing prophylac-
tic drugs, e.g. patients who have a shared genetic compo-
nent between migraine and depression may profit better
from antidepressants than others. A shared genetic com-
ponent may also prompt screening for depression in mi-
graine patients with unrecognized depression.
Investigation of migraine and endophenotypes in migraine
Migraine is a highly heterogeneous disorder. The fre-
quency, severity, and triggering of attacks as well as the
pharmacological effect of migraine drugs vary between
patients. Defining migraine endophenotypes may narrow
down the broad clinical phenotype into more homoge-
neous and pathophysiological relevant phenotypes; facili-
tate clinical trials; and possibly increase power to detect
the putative genetic correlations. Menstrual relation [39]
and premonitory symptoms [40] are previously described
migraine endophenotypes. PRS analysis may identify
more endophenotypes in migraine. Perhaps menstrual
migraine can be characterized by applying the PRS from
other menstrual cycle associated conditions such as
endometriosis [36]. Also, it would be interesting to in-
vestigate whether migraine without aura and migraine
with aura are endophenotypes or genetically distinct dis-
orders. Keeping in mind, that an important property of
endophenotypes is their heritable nature (Table 3), it
may interesting to use PRS to analyze the relation be-
tween migraine and tension-type headache [41];
migraine and secondary headaches (particularly chronic
post-traumatic headache); chronic and episodic mi-
graine, and to investigate whether proneness to medica-
tion overuse is an endophenotype. A recent study
investigating 12 migraine-associated SNPs and drug
Table 3 The criteria for endophenotypes (adapted from Gottesman
et al. [17])
1 The endophenotype is associated with illness in the population
2 The endophenotype is heritable
3 The endophenotype is primarily state independent (manifests in an
individual whether or not illness is active)
4 Within families, the endophenotype and illness co-segregate
5 The endophenotype found in affected family members are found in
non-affected family members at a higher rate than in the general
population
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response found an association between increasing gen-
etic load of migraine and the effect of triptans with odds
ratios of treatment success from 1.3–2.6 (P < 0.05) de-
pending on single SNPs or a genetic load of the 12
migraine-associated SNPs [42]. This encouraging finding
merits further investigation using PRS analysis. It is rele-
vant to investigate pharmacogenetic effects because a
third of patients with migraine do not respond well to
triptans and many more have no or poor response to
prophylactic medication [43]. Perhaps PRS analysis can
also be used to predict efficacy of the Calcitonin Gene-
Related Peptide (CGRP) monoclonal antibodies that
soon become available, presumably at a high cost.
Prediction of case-control status in migraine
Clinical disease prediction of migraine relies exclusively
upon existing classification criteria (the International
Classification of Headache, third edition [44]) as there are
no available objective diagnostic methods to assess mi-
graine status in patients. Frequent migraine attacks may
be associated with several cerebral disorders such as ar-
teriovenous malformations [45], mitochondrial encephal-
opathies [46], and cerebral arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL) [47, 48].
Further, migraine-like attacks may be triggered by differ-
ent vascular events such as cerebral infarction, cervical-
artery dissection, or cerebral venous thrombosis. In the
latter cases, migraine attacks are symptomatic of the
underlying pathology, and symptomatic migraine attacks
are often difficult to distinguish from a primary migraine
disorder. PRS may assist in predicting migraine disease
status in these complex cases and assist in understanding
whether the mechanisms of symptomatic migraine attacks
are different from those of primary migraine attacks.
Additionally, PRS analysis may help to assess whether pa-
tients with organic cerebral disorders have a lower thresh-
old than others for developing migraine attacks. Given a
proper prediction power, the PRS may even assist in the
migraine diagnosis [49]. A study from the Norfolk Island
[50] showed a higher PRS score for patients with migraine
than controls (P = 0.0016); and that a high PRS score re-
sulted in a 3.1-fold increased risk of migraine. This is a
very interesting finding, and the latest migraine GWAS
presents an opportunity to confirm these findings.
Conclusion
PRS analyses have shown successful progress in the re-
search of neuropsychiatric disorders and may inspire mi-
graine research to understand more about the genetic
underpinnings of migraine. PRS may be useful in the in-
vestigation of shared genetic risk with comorbidities, in
studying the relation between primary headache disor-
ders and their sub-forms, and to personalize migraine
treatment.
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